LAS VEGAS — OCT is increasingly useful in diagnosing disorders that affect optical pathways to the brain, a speaker told colleagues.“[OCT technology] is really affecting the way that we approach patients and diagnose their problems. Some of them can be life-threatening in neuro-ophthalmology,” Randy H. Kardon, MD, PhD, said during a press briefing on “Innovations in vision: Nanotech, nearsightedness and neuro-ophthalmology imaging.”
Pfizer and Allergan announced today that their boards of directors have approved a definitive merger agreement in which Pfizer will combine with Allergan.The merger has a stock transaction currently valued at $363.63 per Allergan share, for a total value of approximately $160 billion, based on the closing price of Pfizer common stock of $32.18 on Nov. 20, according to a press release from both companies. Under the proposal, the businesses of Pfizer and Allergan will be combined under Allergan plc, which will be renamed Pfizer plc.
LAS VEGAS — At the American Academy of Ophthalmology annual meeting, Nathan M. Radcliffe, MD, discusses how selective laser trabeculoplasty can be a solution to managing glaucoma, both as a primary therapy and as a replacement therapy for eye drops.
CUMMING, Ga.–(BUSINESS WIRE)–Accuitis, Inc. completes latest financing round and elects Geoffrey Meacham PhD to Board of Directors.
(MedPage Today) — Could be record year for new drug approvals
For more than 150 years, physicians have examined patients’ eyes with a lighted, hand-held instrument called an ophthalmoscope.